Weather , , 0°C

Acute Respiratory Distress Syndrome Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Acute Respiratory Distress Syndrome Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

April 06
17:41 2021
Acute Respiratory Distress Syndrome Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Acute Respiratory Distress Syndrome Market

DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS) , historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of the ARDS Report:

  • Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017– 2030.
  • DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017
  • Among the EU-5 countries, Germany had the highest incident population of ARDS with 148,302 cases.
  • Among the EU-5 countries, Spain had the lowest incident population of 20,839 in 2017.

 

Key Benefits of the ARDS Report:

  • Acute Respiratory Distress Syndrome Market report covers a descriptive overview and comprehensive insight of the Acute Respiratory Distress Syndrome epidemiology and Acute Respiratory Distress Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  • Acute Respiratory Distress Syndrome market report provides insights on the current and emerging therapies.
  • Acute Respiratory Distress Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
  • Acute Respiratory Distress Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome market.

 

Request for Sample Page: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

 

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

 

“The highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS”

 

Request for Sample Page: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

 

The launch of the emerging therapies is expected to significantly impact Acute Respiratory Distress Syndrome treatment scenario in the upcoming years:-

Acute Respiratory Distress Syndrome Drugs covered:

  • Traumakine
  • Bio-11006
  • Ulinastatin
  • MultiStem
  • Solnatide (AP301)
  • APN01 (GSK2586881)
  • GSK2862277
  • IC14
  • Remodulin (Treprostinil Inhalation Solution)
  • And Many Others

 

The key players in Acute Respiratory Distress Syndrome market are:

  • Faron Pharmaceuticals
  • BioMarck Pharmaceuticals
  • Techpool Bio-Pharma
  • Athersys
  • APEPTICO Forschung und Entwicklung GmbH
  • Apeiron Biologics/GlaxoSmithKline
  • GlaxoSmithKline
  • Implicit Bioscience
  • United Therapeutics
  • And Many Others

 

Request for Sample Page: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

 

Table of Contents:

1. Key Insights

2. Executive Summary

3. Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance

4. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

5. Case Reports

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology

7. 7MM Epidemiology Analysis

8. United States Epidemiology

9. EU5 Epidemiology

9.1. Germany Epidemiology

9.2. France Epidemiology

9.3. Italy Epidemiology

9.4. Spain Epidemiology

9.5. United Kingdom Epidemiology

10. Japan Epidemiology

10.1.Assumptions and Rationale

10.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Japan

10.3. Severity-specific Incidence of ARDS in Japan

10.4. Incident Population of ARDS by Risk Factors in Japan

11. Treatment Algorithm, Current Treatment, and Medical Practices

11.1. Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)

12. Proposed Guidelines for ARDS

13. Unmet Needs

14. Off-Label Therapies for ARDS

14.1.Neuromuscular Blocking Agents (NMBAs)

14.2. Inhaled Vasodilators

14.3. Corticosteroids

15. Emerging Therapies

15.1.Key Cross Competition

15.2. Traumakine: Faron Pharmaceuticals

15.3.Bio-11006: BioMarck Pharmaceuticals

15.4.Ulinastatin: Techpool Bio-Pharma

15.5.MultiStem: Athersys

15.6. Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH

List to be continued in the report……

16. Discontinued Products

16.1.APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline

16.2.GSK2862277: GlaxoSmithKline

16.3. IC14: Implicit Bioscience

16.4.Remodulin (Treprostinil Inhalation Solution): United Therapeutics

17. Acute Respiratory Distress Syndrome (ARDS): 7MM Analysis

18. United States: Market Outlook

19. United States Market Size

20. EU-5 Countries: Market Outlook

21. Japan Market Outlook

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. KOL Views

26. Appendix

26.1.Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight­­­

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Related Articles

Calendar

April 2021
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  

Categories